StockNews.AI
MIRA
StockNews.AI
1 min

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

1. MIRA acquires SKNY, enhancing its pipeline with SKNY-1's promising weight loss results.

M&A
0%Current Return
VS
0%S&P 500
$1.6609/12 07:36 AM EDTEvent Start
$1.6609/12 07:36 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The acquisition of SKNY adds a therapeutic candidate with potential high demand, similar to other successful weight-loss drugs which have historically seen positive price impacts upon announcement.

How important is it?

The positive preclinical results and acquisition signify a crucial step in MIRA's strategic growth, directly intersecting with investor interests.

Why Long Term?

Market acceptance and successful trials of SKNY-1 will influence MIRA's long-term valuation, akin to past biotech approvals.

Related Companies

SKNYNVAXPTCT
SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30% weight loss and nicotine craving reversal in preclinical studies. MIAMI, FL / ACCESS Newswire / September 12, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that its stockholders have approved the acquisition of SKNY Pharmaceuticals, Inc. ("SKNY") at the Company's 2025 Annual Meeting of Stockholders.

Related News